| Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL (NCT05259813) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2022-02-28 |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (NCT05024045) | Eli Lilly and Company | 2021-09-30 |
| A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (NCT04849416) | Eli Lilly and Company | 2021-05-14 |
| A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT04540796) | Janssen Research & Development, LLC | 2020-11-20 |
| A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NCT04210219) | Janssen Research & Development, LLC | 2020-07-02 |
| Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (NCT04204057) | Rhizen Pharmaceuticals SA | 2019-11-28 |
| A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion (NCT03190330) | Johnson & Johnson Private Limited | 2019-06-26 |
| CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma (NCT04271410) | Chongqing Precision Biotech Co., Ltd | 2019-06-01 |
| A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT03900598) | Janssen Research & Development, LLC | 2019-04-03 |
| A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting (NCT03720561) | Janssen-Cilag S.p.A. | 2018-10-30 |
| DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia (NCT03265717) | Invectys | 2018-07-25 |
| Project to Improve Communication About Serious Illness - Pilot Study (NCT03746392) | University of Washington | 2018-07-01 |
| CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT (NCT03685786) | Shenzhen Second People's Hospital | 2018-06-01 |
| Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India (NCT03476655) | Johnson & Johnson Private Limited | 2018-04-28 |
| A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT03462719) | Janssen Research & Development, LLC | 2018-04-17 |
| This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax (NCT03343678) | Boehringer Ingelheim | 2018-01-17 |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (NCT03331198) | Juno Therapeutics, a Subsidiary of Celgene | 2017-11-27 |
| A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy (NCT03301207) | Janssen Research & Development, LLC | 2017-10-20 |
| Determination of Blood Tumor Cells (NCT04290923) | University of Zurich | 2017-10-01 |
| Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT03204188) | National Heart, Lung, and Blood Institute (NHLBI) | 2017-09-22 |
| An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) (NCT03289182) | Hoffmann-La Roche | 2017-09-15 |
| Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients (NCT02912754) | Sunnybrook Health Sciences Centre | 2017-03-01 |
| Treatment of Chronic Lymphocytic Leukemia (NCT02757586) | Peking University People's Hospital | 2016-12-01 |
| Combination of Ibrutinib and As2O3 in the Treatment of CLL (NCT02757040) | Peking University People's Hospital | 2016-12-01 |
| Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (NCT02639910) | MorphoSys AG | 2016-11-01 |
| A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms (NCT02842229) | Celgene | 2016-07-20 |
| Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma (NCT02743546) | Janssen Research & Development, LLC | 2016-07-20 |
| a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies (NCT02846584) | Southwest Hospital, China | 2016-07-01 |
| Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib (NCT02759016) | Boehringer Ingelheim | 2016-06-23 |
| A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice (NCT03425591) | Janssen-Cilag Ltd. | 2016-05-11 |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (NCT02733042) | Celgene | 2016-05-11 |
| Humanized CAR-T Therapy for Treatment of B Cell Malignancy (NCT02782351) | Kai Lin Xu; Jun Nian Zheng | 2016-05-01 |
| Phase II Trial GA101 Inbrutinib B CLL (NCT02666898) | French Innovative Leukemia Organisation | 2015-10-01 |
| A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT02406742) | Celgene | 2015-07-27 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (NCT02361346) | Molecular Templates, Inc. | 2015-02-01 |
| Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (NCT01732861) | Celgene | 2012-12-28 |
| Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT01744626) | Celgene Corporation | 2012-12-01 |
| Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) (NCT01373229) | David Rizzieri, MD | 2012-01-01 |
| Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia (NCT01456182) | Afexa Life Sciences Inc | 2011-12-01 |
| Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (NCT01158118) | Washington University School of Medicine | 2011-04-01 |
| BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) (NCT01296932) | Boehringer Ingelheim | 2011-02-11 |
| A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) (NCT01005979) | Emory University | 2010-07-01 |
| A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT00923182) | Genzyme, a Sanofi Company | 2010-02-01 |
| A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies (NCT00861510) | National Heart, Lung, and Blood Institute (NHLBI) | 2009-03-05 |
| Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) (NCT00951457) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2009-03-01 |
| SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) (NCT00871546) | Merck Sharp & Dohme LLC | 2009-03-01 |
| Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL (NCT00738829) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2008-10-01 |
| A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas (NCT00768339) | Aegera Therapeutics | 2008-09-01 |
| A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL) (NCT00545714) | Hoffmann-La Roche | 2007-11-21 |
| Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) (NCT00871663) | Merck Sharp & Dohme LLC | 2006-08-01 |
| Institut Paoli Calmettes Chronic Lymphatic Leukemia Database (NCT02869529) | Institut Paoli-Calmettes | 2006-01-01 |
| Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) (NCT00206726) | Genzyme, a Sanofi Company | 2005-05-01 |
| Family Study of Lymphoproliferative Disorders (NCT00626496) | Mayo Clinic | 2004-04-01 |
| A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia (NCT00220311) | Genzyme, a Sanofi Company | 2000-11-01 |